EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review

Adwoa Dansoa Tabi-Amponsah iD, Sarah Stewart, Graham Hosie, Lisa K Stamp, William J Taylor iD, Nicola Dalbeth

Pharmaceuticals · 23.05.2023 · 16 (6) · 779

DOI: 10.3390/ph16060779 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 23.05.2023. Verfasst von Adwoa Dansoa Tabi-Amponsah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Auckland Health Research Doctoral Scholarship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi. Thus, disease remission is a potential goal of urate-lowering therapy. In 2016, preliminary gout remission criteria were developed by a large group of rheumatologists and researchers with expertise in gout. The preliminary gout remission criteria were defined as: serum urate < 0.36 mmol/L (6 mg/dL); an absence of gout flares; an absence of tophi; pain due to gout < 2 on a 0–10 scale; and a patient global assessment < 2 on a 0–10 scale over a 12-month period. In this critical review, we describe the development of the preliminary gout remission criteria, the properties of the preliminary gout remission criteria, and clinical studies of gout remission in people taking urate-lowering therapy. We also describe a future research agenda for gout remission.

Schlagwörter

Stichwörter der Autor:innen

goutgout remissionpreliminary gout remission criteriaurate-lowering therapy

Autor:innen und Institutionen

  • Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand.
  • School of Clinical Sciences, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland 0627, New Zealand.
  • Department of Medicine, University of Otago, Christchurch 8011, New Zealand.
  • Department of Medicine, University of Otago, Wellington 6242, New Zealand.

ORCID-Profile: Adwoa Dansoa Tabi-Amponsah, William J Taylor

Förderung

  • University of Auckland Health Research Doctoral Scholarship

Zitieren

APA

Tabi-Amponsah, A. D., Stewart, S., Hosie, G., Stamp, L. K., Taylor, W. J., & Dalbeth, N. (2023). Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review. Pharmaceuticals, 16(6), 779. https://doi.org/10.3390/ph16060779

Vancouver

Tabi-Amponsah AD, Stewart S, Hosie G, Stamp LK, Taylor WJ, Dalbeth N. Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review. Pharmaceuticals. 2023;16(6):779. doi:10.3390/ph16060779

BibTeX
@article{TabiAmponsah2023,
  author = {Tabi-Amponsah, Adwoa Dansoa and Stewart, Sarah and Hosie, Graham and Stamp, Lisa K and Taylor, William J and Dalbeth, Nicola},
  title = {Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {6},
  pages = {779},
  doi = {10.3390/ph16060779}
}
Kostenlos starten →